^
Association details:
| Biomarker: | MYD88 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Vonjo (pacritinib) (JAK2 inhibitor, FLT3 inhibitor, CSF-1R inhibitor, ACVR1 inhibitor, IRAK-1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3300 Pacritinib Blocks Key Pro-Survival Signaling Related to Mutated MYD88, Produces High Levels of Apoptosis and Overcomes Mutated BTKCys481 Related BTK-Inhibitor Resistance
Published date:
11/02/2023
Excerpt:
Pacritinib produced higher levels of apoptosis in MYD88-mutated WM (BCWM.1) and ABC DLBCL (TMD-8)...Pacritinib more broadly extinguishes mutated MYD88 pro-survival signaling cascades (Fig 1.) and demonstrates high levels of apoptotic activity in mutated MYD88 WM and ABC DLBCL cells versus selective covalent BTK-inhibitors.
